News
06-02-2014, 05:10 AM
Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.
More... (http://www.news-medical.net/news/20140602/Nektar-reports-etirinotecan-pegol-Phase-2-study-results-in-patients-with-Avastin-refractory-high-grade-glioma.aspx)
More... (http://www.news-medical.net/news/20140602/Nektar-reports-etirinotecan-pegol-Phase-2-study-results-in-patients-with-Avastin-refractory-high-grade-glioma.aspx)